FI4076652T3 - Farmaseuttisesti hyväksyttävä atrasentanin suola käytettäväksi iga-nefropatiaan hoitomenetelmässä - Google Patents

Farmaseuttisesti hyväksyttävä atrasentanin suola käytettäväksi iga-nefropatiaan hoitomenetelmässä

Info

Publication number
FI4076652T3
FI4076652T3 FIEP20903533.6T FI20903533T FI4076652T3 FI 4076652 T3 FI4076652 T3 FI 4076652T3 FI 20903533 T FI20903533 T FI 20903533T FI 4076652 T3 FI4076652 T3 FI 4076652T3
Authority
FI
Finland
Prior art keywords
atrasentan
acceptable salt
pharmaceutically acceptable
use according
subject
Prior art date
Application number
FIEP20903533.6T
Other languages
English (en)
Finnish (fi)
Inventor
Philip Thomas Frohlich
Andrew James King
Chidambaram Ramachandran
Sarah Beth Noonberg
Original Assignee
Chinook Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Chinook Therapeutics Inc filed Critical Chinook Therapeutics Inc
Application granted granted Critical
Publication of FI4076652T3 publication Critical patent/FI4076652T3/fi

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/4025—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil not condensed and containing further heterocyclic rings, e.g. cromakalim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/12—Antidiuretics, e.g. drugs for diabetes insipidus
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/472—Non-condensed isoquinolines, e.g. papaverine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Diabetes (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Molecular Biology (AREA)
  • Virology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Enzymes And Modification Thereof (AREA)
FIEP20903533.6T 2019-12-17 2020-12-16 Farmaseuttisesti hyväksyttävä atrasentanin suola käytettäväksi iga-nefropatiaan hoitomenetelmässä FI4076652T3 (fi)

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
US201962949115P 2019-12-17 2019-12-17
US202063005003P 2020-04-03 2020-04-03
US202063072699P 2020-08-31 2020-08-31
US202063084739P 2020-09-29 2020-09-29
US202063125205P 2020-12-14 2020-12-14
PCT/US2020/065311 WO2021126977A1 (en) 2019-12-17 2020-12-16 Methods of treating iga nephropathy with atrasentan

Publications (1)

Publication Number Publication Date
FI4076652T3 true FI4076652T3 (fi) 2026-02-10

Family

ID=76478538

Family Applications (1)

Application Number Title Priority Date Filing Date
FIEP20903533.6T FI4076652T3 (fi) 2019-12-17 2020-12-16 Farmaseuttisesti hyväksyttävä atrasentanin suola käytettäväksi iga-nefropatiaan hoitomenetelmässä

Country Status (21)

Country Link
US (11) US20210353593A1 (cg-RX-API-DMAC7.html)
EP (2) EP4076652B1 (cg-RX-API-DMAC7.html)
JP (3) JP7624995B2 (cg-RX-API-DMAC7.html)
KR (1) KR20230015874A (cg-RX-API-DMAC7.html)
CN (3) CN116327758A (cg-RX-API-DMAC7.html)
AU (1) AU2020404984A1 (cg-RX-API-DMAC7.html)
BR (1) BR112022012075A2 (cg-RX-API-DMAC7.html)
CA (1) CA3161516A1 (cg-RX-API-DMAC7.html)
DK (1) DK4076652T3 (cg-RX-API-DMAC7.html)
FI (1) FI4076652T3 (cg-RX-API-DMAC7.html)
HR (1) HRP20260121T1 (cg-RX-API-DMAC7.html)
IL (1) IL293921A (cg-RX-API-DMAC7.html)
LT (1) LT4076652T (cg-RX-API-DMAC7.html)
MX (1) MX2022007471A (cg-RX-API-DMAC7.html)
PH (1) PH12022551456A1 (cg-RX-API-DMAC7.html)
PL (1) PL4076652T3 (cg-RX-API-DMAC7.html)
PT (1) PT4076652T (cg-RX-API-DMAC7.html)
RS (1) RS67746B1 (cg-RX-API-DMAC7.html)
SI (1) SI4076652T1 (cg-RX-API-DMAC7.html)
TW (3) TW202615002A (cg-RX-API-DMAC7.html)
WO (1) WO2021126977A1 (cg-RX-API-DMAC7.html)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HRP20260121T1 (hr) 2019-12-17 2026-03-13 Chinook Therapeutics, Inc. Farmaceutski prihvatljiva sol atrasentana za uporabu u postupku za liječenje iga nefropatije
CN114910647A (zh) * 2022-05-07 2022-08-16 浙江大学 细丝蛋白-A-IgG抗体在制备检测血管内皮损伤试剂盒中的应用
WO2023220930A1 (en) * 2022-05-17 2023-11-23 Increvet, Inc. Veterinary pharmaceutical formulations cross-references to related applications
JP2025517355A (ja) * 2022-05-19 2025-06-05 チヌーク セラピューティクス,インコーポレイテッド アトラセンタンを用いた巣状分節性糸球体硬化症の治療方法
WO2024073672A1 (en) 2022-09-30 2024-04-04 Travere Therapeutics, Inc. Combination therapy with sparsentan and a sglt2 inhibitor for treating kidney diseases or disorders
US20260130933A1 (en) * 2022-10-05 2026-05-14 Daewoong Pharmaceutical Co., Ltd. Pharmaceutical composition for prevention or treatment of nephropathy and/or diabetes mellitus, comprising enavogliflozin
AU2023366516A1 (en) * 2022-10-28 2025-05-15 Aduro Biotech Holdings, Europe B.V. Treatment of iga nephropathy using an endothelin receptor antagonist and an april binding antibody
WO2024099272A1 (zh) * 2022-11-07 2024-05-16 信瑞诺医药(上海)有限公司 用于治疗IgA肾病的内皮素受体拮抗剂和糖皮质激素的组合
TW202604476A (zh) * 2024-06-21 2026-02-01 大陸商深圳信立泰藥業股份有限公司 內皮素a(eta)受體拮抗劑聯用sglt-2抑制劑的醫藥用途

Family Cites Families (53)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4522811A (en) 1982-07-08 1985-06-11 Syntex (U.S.A.) Inc. Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US5260203A (en) 1986-09-02 1993-11-09 Enzon, Inc. Single polypeptide chain binding molecules
EP0281604B1 (en) 1986-09-02 1993-03-31 Enzon Labs Inc. Single polypeptide chain binding molecules
US4946778A (en) 1987-09-21 1990-08-07 Genex Corporation Single polypeptide chain binding molecules
JP3101690B2 (ja) 1987-03-18 2000-10-23 エス・ビィ・2・インコーポレイテッド 変性抗体の、または変性抗体に関する改良
US5236940A (en) 1988-12-15 1993-08-17 Rhone-Poulenc Sante Pharmaceutical compositions, 2-benzothiazolamine derivatives, and their preparation
DE69233528T2 (de) 1991-11-25 2006-03-16 Enzon, Inc. Verfahren zur Herstellung von multivalenten antigenbindenden Proteinen
US7208517B1 (en) 1994-08-19 2007-04-24 Abbott Labortories Endothelin antagonists
US6946481B1 (en) 1994-08-19 2005-09-20 Abbott Laboratories Endothelin antagonists
US7365093B2 (en) 1994-08-19 2008-04-29 Abbott Laboratories Endothelin antagonists
US20020062121A1 (en) 1995-05-16 2002-05-23 Karl Tryggvason Perfusion apparatus and methods for pharmaceutical delivery
ES2259803T3 (es) 1996-02-13 2006-10-16 Abbott Laboratories Nuevos derivados de pirrolidina sustituidos con benzo-1,3-dioxolilo y benzofuranilo como antagonistas de endostelina.
US20040191774A1 (en) 2001-09-11 2004-09-30 Moskowitz David W Endothelin-1 promoter polymorphism
AU2003221042A1 (en) 2002-03-22 2003-10-08 Kissei Pharmaceutical Co., Ltd. Preventive or therapeutic agent for kidney disease
US20070134247A9 (en) 2002-04-12 2007-06-14 Ramot At Tel Aviv University Ltd. Prevention of brain inflammation as a result of induced autoimmune response
US20030229906A1 (en) 2002-04-15 2003-12-11 Gelman Irwin H. Methods and compositions for the treatment of disorders of HIV infection
US9388427B2 (en) 2002-12-02 2016-07-12 Biovec, Llc In vivo and ex vivo gene transfer into renal tissue using gutless adenovirus vectors
US7410483B2 (en) 2003-05-23 2008-08-12 Novare Surgical Systems, Inc. Hand-actuated device for remote manipulation of a grasping tool
WO2005120571A2 (en) 2004-06-07 2005-12-22 Ramot At Tel Aviv University Ltd. Method of passive immunization against disease or disorder characterized by amyloid aggregation with diminished risk of neuroinflammation
WO2006034234A1 (en) 2004-09-17 2006-03-30 Abbott Laboratories Crystalline form 3 of atrasentan hydrochloride
WO2006034084A1 (en) 2004-09-17 2006-03-30 Abbott Laboratories Crystalline form 2 of atrasentan hydrochloride
WO2006034085A1 (en) 2004-09-17 2006-03-30 Abbott Laboratories Crystalline form of atrasentan hydrochloride
US20060189675A1 (en) 2004-09-17 2006-08-24 Steve King Crystalline form of a drug
WO2007109244A2 (en) 2006-03-21 2007-09-27 Morehouse School Of Medicine Novel nanoparticles for delivery of active agents
KR20080108570A (ko) * 2006-03-27 2008-12-15 제넨테크, 인크. 신장 질환을 치료하는 방법
WO2007119214A2 (en) 2006-04-13 2007-10-25 Actelion Pharmaceuticals Ltd Endothelin receptor antagonists for early stage idiopathic pulmonary fibrosis
ZA200902814B (en) 2007-01-16 2010-08-25 Musc Found For Res Dev Compositions and methods for diagnosing, treating, and preventing prostate conditions
CN101801936B (zh) 2007-07-31 2012-10-03 吉利德科罗拉多公司 安立生坦的代谢物和衍生物
CA2697057A1 (en) 2007-08-22 2009-02-26 Gilead Colorado, Inc. Therapy for complications of diabetes
US20120083421A1 (en) 2008-10-16 2012-04-05 The Trustees Of Columbia University In The City Of New York Use of urinary ngal to diagnose and monitor hiv-associated nephropathy (hivan)
WO2010114801A1 (en) 2009-03-31 2010-10-07 Ligand Pharmaceuticals Inc. Oral formulations of diphenylsulfonamide endothelin and angiotensin ii receptor agonists to treat elevated blood pressure and diabetic nephropathy
WO2011070049A1 (en) 2009-12-09 2011-06-16 INSERM (Institut National de la Santé et de la Recherche Médicale) Endothelin inhibitors for the treatment of rapidly progressive glomerulonephritis
US9255931B2 (en) 2010-06-24 2016-02-09 Morehouse School Of Medicine Method and compositions for the treatment and detection of endothelin-1 related kidney diseases
CN103025670B (zh) 2010-07-28 2016-08-10 日本电气硝子株式会社 荧光体封入用毛细管的制造方法、荧光体封入用毛细管、波长变换部件和波长变换部件的制造方法
JP2016512201A (ja) * 2013-03-08 2016-04-25 アッヴィ・インコーポレイテッド 急性腎障害の治療方法
US9855245B2 (en) 2013-04-30 2018-01-02 Abbvie Inc. Methods for improving lipid profiles using atrasentan
PE20160221A1 (es) 2013-07-08 2016-05-22 Abbvie Inc Formas de dosificacion farmaceuticas estabilizadas que comprenden atrasentan
NL2011406C2 (en) 2013-09-06 2015-03-10 Bionovion Holding B V Method for obtaining april-binding peptides, process for producing the peptides, april-binding peptides obtainable with said method/process and use of the april-binding peptides.
US8962675B1 (en) 2013-09-12 2015-02-24 Abbvie Inc. Atrasentan mandelate salts
WO2016073846A1 (en) * 2014-11-07 2016-05-12 Abbvie Inc. Methods of treating ckd using predictors of fluid retention
NL2014108B1 (en) 2015-01-09 2016-09-30 Aduro Biotech Holdings Europe B V Altered april binding antibodies.
US20170014386A1 (en) 2015-07-16 2017-01-19 Abbvie, Inc. Treatment of Multidrug-Resistant Nephrotic Syndrome (MDR-NS) in Children
IL300122A (en) * 2015-11-18 2023-03-01 Merck Sharp ַ& Dohme Llc Substances that bind to PD1 and/or LAG3
CA3010593C (en) 2016-01-05 2024-02-13 University Of Leicester Methods for inhibiting fibrosis in a subject in need thereof
JP2019530713A (ja) * 2016-10-13 2019-10-24 レトロフィン, インコーポレイテッド 腎臓疾患または障害を処置するためのビフェニルスルホンアミド化合物
IL294410B2 (en) 2016-11-23 2024-02-01 Chemocentryx Inc A method for the treatment of focal segmental tuberous sclerosis
MX386699B (es) 2017-10-11 2025-03-19 Chemocentryx Inc Tratamiento de glomerulosclerosis segmentaria focal con antagonistas ccr2
LT3716979T (lt) 2017-11-30 2025-07-10 Idorsia Pharmaceuticals Ltd 4-pirimidinsulfamido darinio derinys su sglt-2 inhibitoriumi, skirtas su endotelinu susijusių ligų gydymui
US20220304979A1 (en) 2019-12-17 2022-09-29 Chinook Therapeutics, Inc. Methods of reducing disease flares
HRP20260121T1 (hr) 2019-12-17 2026-03-13 Chinook Therapeutics, Inc. Farmaceutski prihvatljiva sol atrasentana za uporabu u postupku za liječenje iga nefropatije
US20230270718A1 (en) 2020-04-10 2023-08-31 Chinook Therapeutics, Inc. Methods of treating diabetic kidney disease
US20220243994A1 (en) 2021-02-04 2022-08-04 Northrop Grumman Systems Corporation Metal woodpile capillary wick

Also Published As

Publication number Publication date
CA3161516A1 (en) 2021-06-24
US20220288027A1 (en) 2022-09-15
JP2026090302A (ja) 2026-06-02
LT4076652T (lt) 2026-02-25
DK4076652T3 (da) 2026-03-02
JP2023507739A (ja) 2023-02-27
KR20230015874A (ko) 2023-01-31
US20230355580A1 (en) 2023-11-09
PH12022551456A1 (en) 2023-10-23
EP4710928A2 (en) 2026-03-18
IL293921A (en) 2022-08-01
US12582631B2 (en) 2026-03-24
EP4076652B1 (en) 2025-12-03
BR112022012075A2 (pt) 2022-08-30
CN113272013A (zh) 2021-08-17
MX2022007471A (es) 2022-08-17
US11491137B2 (en) 2022-11-08
PL4076652T3 (pl) 2026-03-23
US20210353593A1 (en) 2021-11-18
US20240108599A1 (en) 2024-04-04
US20230364055A1 (en) 2023-11-16
US12121509B2 (en) 2024-10-22
EP4710928A3 (en) 2026-04-15
EP4076652A1 (en) 2022-10-26
CN116327758A (zh) 2023-06-27
JP2025060686A (ja) 2025-04-10
SI4076652T1 (sl) 2026-03-31
JP7821870B2 (ja) 2026-02-27
TW202545517A (zh) 2025-12-01
US20230129646A1 (en) 2023-04-27
US20230355579A1 (en) 2023-11-09
JP7624995B2 (ja) 2025-01-31
US20220304978A1 (en) 2022-09-29
TW202130350A (zh) 2021-08-16
US12521369B2 (en) 2026-01-13
CN116173014A (zh) 2023-05-30
TW202615002A (zh) 2026-04-16
RS67746B1 (sr) 2026-03-31
US12370174B2 (en) 2025-07-29
TWI914232B (zh) 2026-02-01
AU2020404984A1 (en) 2022-07-14
US20220288026A1 (en) 2022-09-15
HRP20260121T1 (hr) 2026-03-13
TWI875895B (zh) 2025-03-11
US20250281454A1 (en) 2025-09-11
PT4076652T (pt) 2026-02-12
WO2021126977A1 (en) 2021-06-24
WO2021126977A9 (en) 2021-07-22
US20250120945A1 (en) 2025-04-17
EP4076652A4 (en) 2024-01-03
US11998526B2 (en) 2024-06-04

Similar Documents

Publication Publication Date Title
HRP20110969T4 (hr) Pimobendan za upotrebu za smanjenje veličine srca kod sisavaca koji pate od srčane insuficijencije
RU2378018C2 (ru) Фармацевтические препараты и их применение для профилактики удара, диабета и/или застойной сердечной недостаточности
JP2003527325A5 (cg-RX-API-DMAC7.html)
RU2002107985A (ru) Применение ингибиторов ренин-ангиотензиновой системы для профилактики сердечно-сосудистых явлений
HUP0400475A2 (hu) Egy AT1 receptor antagonista vagy egy ACE inhibitor vagy egy HMG-CO-A reduktáz inhibitor közül legalább két vegyület kombinációját tartalmazó gyógyszerkészítmények és alkalmazásuk
Smith et al. Antihypertensive therapies.
RU2019119129A (ru) Способ лечения фокально-сегментарного гломерулосклероза
Zhang et al. Management of hypertension using olmesartan alone or in combination
US20030171415A1 (en) Pharmaceutical combination of angiotensin II antagonists and angiotensin I converting enzyme inhibitors
RU2015110979A (ru) Комбинации ингибиторов sglt 2 и антигипертензивных лекарственных средств
AU2001295465A1 (en) Pharmaceutical combination of angiotensin II antagonists and ace inhibitors
Shibata et al. Renin angiotensin aldosterone system blockers
RU2006135205A (ru) Применение антагонистов рецептора ангиотензина ii для лечения острого инфаркта миокарда
Fabiani et al. Spectrum of use for the angiotensin-receptor blocking drugs
JP2010519235A5 (cg-RX-API-DMAC7.html)
US20080114046A1 (en) Pharmaceutical Combination of Angiotensin II Antagonists and Angiotensin I Converting Enzyme Inhibitors
US20030158223A1 (en) Pharmaceutical combination of angiotensin II antagonists and angiotensin I converting enzyme inhibitors
JP2005511631A (ja) 脳血管障害発作の急性期における高血圧症の治療
Ma et al. Management of Hypertension Using Olmesartan Alone or in Combination
JP2008133229A (ja) 医薬組成物
JP2004520268A (ja) アンギオテンシンii拮抗剤とアンギオテンシンi変換酵素阻害剤とを含有する医薬組成物
Giles et al. An evaluation of the efficacy of olmesartan medoxomil in Black patients with hypertension
RU2024137883A (ru) Способы лечения фокально-сегментарного гломерулосклероза с помощью атразентана
Manolis et al. [PP. 35.04]: ACE INHIBITORS CONFER MYOCARDIAL INFARCTION PROTECTION WHEN BLOOD PRESSURE REDUCTION IS MODEST
Liu et al. [PP. 35.05]: EFFECT OF ANGIOTENSIN RECEPTOR BLOCKERS ON FLOW MEDIATED VASODILATION: A META-ANALYSIS OF RANDOMIZED CONTROLLED TRIALS